<DOC>
	<DOCNO>NCT01600599</DOCNO>
	<brief_summary>The purpose study assess efficacy IV Tranexamic Acid topical Tranexamic Acid control post op bleed follow Coronary Artery Bypass Graft Surgery use Cardiopulmonary Bypass .</brief_summary>
	<brief_title>Reducing Post Operative Bleeding Following Cabg</brief_title>
	<detailed_description>Coagulopathy common problem open heart surgery use cardiopulmonary bypass ( CPB ) . Some bleeding significant enough require early re-exploration control hemorrhage 2-4 % patient . ( 1,2 ) In adult , excessive post-operative bleeding occur association repeat operation , emergency procedure , female gender , small body mass index , old age , peripheral vascular disease , renal insufficiency ( creatinine &gt; 1.8g/dL ) , poor nutrition ( albumin &lt; 4g/dL ) patient experience prolonged CPB duration . ( 3,4 ) Factors contribute coagulopathy coronary artery bypass grafting ( CABG ) use CPB include thrombocytopenia , acquire platlet dysfunction , loss clotting factor , free heparin increase fibrinolysis . ( 5-7 ) . Lemmer Colleagues ( 8 ) find extracorporeal circulation result significant fibrinolysis , reflect increased concentration plasmin fibrin degradation product ( FDP ) , deleterious effect platlet function . Fibrinolysis find responsible 25-45 % significant post-bypass bleeding . ( 9 ) Many antifibrinolytic agent use reduce post-bypass bleeding . These include Îµ- Aminocaproic Acid ( 10 ) , Aprotinin ( 11 ) Tranexamic Acid ( TA ) ( 12 ) . TA find bind lysine binding site plasmin plasminogen . Saturation sit displaces plasminogen fibrin surface thus inhibit fibrinolysis. ( 13 ) . TA use systemically topically . Due natural barrier property pericardium , prevents free diffusion substance , experimental study show local application different medication pericardial cavity lead desirable therapeutic effect without significant systemic absorption . ( 14-16 ) There systemic review meta-analysis study do look 8 trial ( 622 patient ) use topical antifibrinolytic agent ( aprotinin tranexamic acid ) . No adverse effect report following usage topical antifibrinolytics . ( 17 ) Topical TA also successfully use control bleed bladder , gynaecological , oral , &amp; oropharyngeal surgery . ( 18-20 ) There author thus far compare application intravenous TA combination application intravenous TA topical TA . This study base hypothesis combination intravenous ( IV ) TA topical TA administration significantly reduce amount post-op bleeding significantly follow CABG use CPB .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>primary isolate CABG patient combined procedure redosurgery bleed diathesis ( Haemophilia platelet count ,100 x 109 L1 ) renal impairment ( Creatinine &gt; 130umol/L ) know allergy TA recent ( &lt; 7 day surgery ) intake antiplatelets ( eg Aspirin , Clopidogrel , Ticlid ) heparin administration within 48 hour operation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>